A lipid nanoparticle (LNP) formulation, surface-functionalized with an anti-PD-L1 therapeutic antibody (αPD-L1), was capable of actively targeting and delivering dinaciclib, a cyclin-dependent kinase inhibitor, to mouse and human tumor-associated myeloid cells (TAMCs) by recognizing highly expressed PD-L1 in myeloid cells, including BMDMs, microglia, and myeloid-derived suppressor cells. Here, CD274 is linked to neoplasm.